| Nipple Aspirate Fluid in Detecting Breast Cancer (NCT03715959) | Ohio State University Comprehensive Cancer Center | 2020-12-10 |
| Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer (NCT04081389) | Roswell Park Cancer Institute | 2019-12-06 |
| Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy (NCT03872388) | M.D. Anderson Cancer Center | 2019-09-23 |
| Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted (NCT04185311) | Jonsson Comprehensive Cancer Center | 2019-07-10 |
| Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer (NCT03644589) | University of Washington | 2019-04-01 |
| Evaluation of Mammographic Breast Density in Participants with Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502 (NCT03609021) | Alliance for Clinical Trials in Oncology | 2019-02-26 |
| Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer (NCT03599453) | Roswell Park Cancer Institute | 2019-01-09 |
| Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer (NCT03544125) | OHSU Knight Cancer Institute | 2018-05-03 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery (NCT03326258) | National Cancer Institute (NCI) | 2018-04-20 |
| IACS-010759 in Advanced Cancers (NCT03291938) | M.D. Anderson Cancer Center | 2017-11-13 |
| Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer (NCT03213041) | Northwestern University | 2017-09-14 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer (NCT03154190) | Stanford University | 2017-08-08 |
| Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer (NCT03106077) | M.D. Anderson Cancer Center | 2017-06-05 |
| Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer (NCT02971761) | City of Hope Medical Center | 2017-06-01 |
| Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery (NCT03044730) | Northwestern University | 2017-05-25 |
| Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) (NCT02993068) | M.D. Anderson Cancer Center | 2017-04-18 |
| Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca (NCT02957968) | Virginia Commonwealth University | 2017-01-24 |
| Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy (NCT02945579) | M.D. Anderson Cancer Center | 2017-01-20 |
| DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer (NCT02744053) | M.D. Anderson Cancer Center | 2016-11-07 |
| Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer (NCT02876107) | M.D. Anderson Cancer Center | 2016-10-06 |
| Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis (NCT02774681) | Northwestern University | 2016-08-31 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (NCT02432963) | City of Hope Medical Center | 2016-06-14 |
| Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (NCT02567396) | National Cancer Institute (NCI) | 2016-06-01 |
| FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy (NCT02398773) | National Cancer Institute (NCI) | 2016-05-04 |
| Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (NCT02648477) | City of Hope Medical Center | 2016-03-28 |
| Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer (NCT02672475) | Vanderbilt-Ingram Cancer Center | 2016-03-01 |
| Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer (NCT02627430) | National Cancer Institute (NCI) | 2016-03-01 |
| Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy (NCT02445391) | ECOG-ACRIN Cancer Research Group | 2015-10-20 |
| Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer (NCT02488967) | NRG Oncology | 2015-07-26 |
| 18F-FSPG PET/CT for Cancer Patients on Therapy (NCT02599194) | Andrei Iagaru | 2015-07-01 |
| Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy (NCT02411656) | M.D. Anderson Cancer Center | 2015-06-11 |
| Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer (NCT02457910) | Vanderbilt-Ingram Cancer Center | 2015-06-01 |
| mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (NCT02208375) | M.D. Anderson Cancer Center | 2014-11-11 |
| Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer (NCT02120469) | City of Hope Medical Center | 2014-10-01 |
| Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy (NCT01957514) | University of Washington | 2013-10-28 |
| Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer (NCT01846091) | Mayo Clinic | 2013-04-09 |
| Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer (NCT01750073) | University of Nebraska | 2012-12-07 |
| Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer (NCT01624441) | National Cancer Institute (NCI) | 2012-08-21 |
| Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer (NCT01575522) | National Cancer Institute (NCI) | 2012-03-01 |
| Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer (NCT01525966) | City of Hope Medical Center | 2012-02-15 |
| MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer (NCT01319539) | National Cancer Institute (NCI) | 2011-04-01 |
| Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors (NCT01281150) | National Cancer Institute (NCI) | 2011-01-01 |
| Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery (NCT01276496) | National Cancer Institute (NCI) | 2010-12-01 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer (NCT01238133) | National Cancer Institute (NCI) | 2010-12-01 |
| Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer (NCT01145430) | National Cancer Institute (NCI) | 2010-06-01 |
| Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer (NCT00785291) | National Cancer Institute (NCI) | 2008-10-13 |